Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.

Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis

Banov, Charles H., Lieberman, Phil · 2001 · Annals of Allergy, Asthma & Immunology

Abstract

Background Azelastine hydrochloride is an antihistamine with anti-inflammatory properties that is available in the United States in a nasal spray formulation for the treatment of seasonal allergic rhinitis. Vasomotor (perennial nonallergic) rhinitis (VMR) is a noninfectious, chronic rhinitis usually not associated with inflammatory cell infiltration.Objective Two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials were conducted to determine whether patients with symptoms of VMR (rhinorrhea, sneezing, postnasal drip, and nasal congestion) could be effectively treated with azelastine nasal spray.Methods All of the patients who participated in the trials had a diagnosis of VMR, symptoms for at least 1 year, negative skin tests for a mixed panel of seasonal and perennial allergens, and a nasal cytology examination negative for eosinophils. After a 1-week, single-blind, placebo lead-in period, patients who met the symptom severity qualification criteria were randomized to receive either azelastine nasal spray (two sprays per nostril twice daily, 1.1 mg/day) or placebo nasal spray for 21 days. Patients recorded the severity of their VMR symptoms on diary cards each morning and evening of the trial using a four-point symptom rating scale (0 = none to 3 = severe). The primary efficacy variable was the overall reduction from baseline in the total vasomotor rhinitis symptom score (TVRSS) over the 21-day, double-blind treatment period.Results In both studies, azelastine nasal spray significantly (study 1, P = .002; study 2, P = .005) reduced the TVRSS from baseline when compared with placebo. Significant improvement was observed within the first week and improvement in all symptoms favored treatment with azelastine nasal spray. No serious or unexpected adverse events were reported in either study. Bitter taste (19% vs 2%) was the only adverse experience that occurred with a statistically significantly greater incidence in the azelastine group than in the placebo group.Conclusions This is the first demonstration of the efficacy of an antihistamine in the therapy of VMR in two double-blind, placebo-controlled clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1081-1206(10)62352-6

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 4

  1. Economides, 1999, Vasomotor rhinitis: making the diagnosis and determining therapy, J Respir Dis, 20, 463
  2. Baumgarten, 1994, Modification of allergen-induced symptoms and mediator release by intranasal azelastine, J Pharmacol U Ther, 3, 43
  3. Pearlman, 1999, Azelastine nasal spray and skin test reactivity to histamine in rhinitis patients, Ann Allergy Asthma Immunol, 82, 89
  4. Matsumura, 1990, Inhibitory effects of azelastine on leukotriene B4, C4, and D4 release and production by bronchial asthmatic eosinophils, Respir Res, 9, 206

Cited by

See all 135

Metadata

Authors
Banov, C. H., & Lieberman, P.
Corresponding author
Banov, Charles H.
Venue
Annals of Allergy, Asthma & Immunology
Publisher
Elsevier BV
Published
2001-01
Volume
86
Issue
1
Pages
28-35
ISSN
1081-1206 (ISSN-L)
OpenAlex
W2023228660
Cited by
135
References
40
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2023: 8 · 2022: 1 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 7 · 2017: 7 · 2016: 7 · 2015: 9 · 2014: 6 · 2013: 3 · 2012: 4
FWCI
2.21
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • Annals of Allergy Asthma & Immunology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Otorhinolaryngology › Sinusitis and nasal conditions
  • Health Sciences › Medicine › Surgery › Nasal Surgery and Airway Studies
Keywords
azelastine, nasal spray, vasomotor rhinitis, antihistamines, anti-inflammatory agents, rhinitis symptom scores
MeSH terms
Administration, Intranasal, Adolescent, Adult, Aged, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Phthalazines, Placebos, Rhinitis, Vasomotor, Therapeutic Equivalency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. https://app.cochat.ai/papers/10.1016/s1081-1206(10)62352-6
The paper
Banov, C. H., & Lieberman, P. (2001). Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/s1081-1206(10)62352-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.